Chimerix (NASDAQ:CMRX - Get Free Report)'s stock had its "neutral" rating reiterated by investment analysts at Wedbush in a research note issued to investors on Wednesday, MarketBeat.com reports. They presently have a $8.55 price objective on the biopharmaceutical company's stock, up from their previous price objective of $7.00. Wedbush's target price would indicate a potential upside of 1.42% from the company's previous close.
Separately, HC Wainwright reissued a "neutral" rating and set a $8.55 price objective (down previously from $11.00) on shares of Chimerix in a report on Wednesday.
Get Our Latest Research Report on CMRX
Chimerix Stock Performance
Shares of NASDAQ CMRX remained flat at $8.43 during midday trading on Wednesday. The stock had a trading volume of 7,018,814 shares, compared to its average volume of 2,037,837. Chimerix has a 52 week low of $0.75 and a 52 week high of $8.47. The stock has a market capitalization of $758.16 million, a P/E ratio of -8.97 and a beta of 0.32. The firm has a 50-day moving average price of $4.34 and a two-hundred day moving average price of $2.32.
Insider Transactions at Chimerix
In related news, CEO Michael T. Andriole sold 7,370 shares of the business's stock in a transaction that occurred on Thursday, February 13th. The stock was sold at an average price of $4.52, for a total value of $33,312.40. Following the completion of the sale, the chief executive officer now owns 609,603 shares in the company, valued at $2,755,405.56. The trade was a 1.19 % decrease in their position. The transaction was disclosed in a filing with the SEC, which is available through the SEC website. Over the last 90 days, insiders sold 20,760 shares of company stock valued at $91,175. 13.10% of the stock is owned by corporate insiders.
Institutional Trading of Chimerix
Hedge funds have recently bought and sold shares of the company. Bender Robert & Associates bought a new stake in Chimerix in the 4th quarter worth approximately $37,000. Susquehanna Fundamental Investments LLC bought a new stake in Chimerix in the fourth quarter valued at approximately $59,000. Jane Street Group LLC bought a new stake in Chimerix in the fourth quarter valued at approximately $62,000. Diadema Partners LP bought a new stake in Chimerix in the fourth quarter valued at approximately $101,000. Finally, Squarepoint Ops LLC bought a new stake in Chimerix in the fourth quarter valued at approximately $130,000. Institutional investors own 45.42% of the company's stock.
Chimerix Company Profile
(
Get Free Report)
Chimerix, Inc, a biopharmaceutical company, develops medicines to improve and extend the lives of patients facing deadly diseases. Its pipeline products include ONC201 a program that is in Phase 3 clinical trial for treating patients with H3 K27M-mutant diffuse glioma, as well as in Phase 2 clinical trial for the treatment of rare neuroendocrine tumors; and ONC206, an imipridone, Dopamine Receptor D2 (DRD2) antagonist, and caseinolytic protease P (ClpP) agonist, which is in Phase 1 clinical trial for adult and pediatric patients with primary central nervous system tumors.
Featured Articles
Before you consider Chimerix, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Chimerix wasn't on the list.
While Chimerix currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
MarketBeat has just released its list of 20 stocks that Wall Street analysts hate. These companies may appear to have good fundamentals, but top analysts smell something seriously rotten. Are any of these companies lurking around your portfolio?
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
